Objective To review the epidemiology of gout and associated comorbidities. Methods We
review the key published studies of the epidemiology of gout and associated comorbidities …

Background New drugs and new evidence concerning the use of established treatments
have become available since the publication of the first European League Against …

Objective To provide guidance for the management of gout, including indications for and
optimal use of urate‐lowering therapy (ULT), treatment of gout flares, and lifestyle and other …

Background Cardiovascular risk is increased in patients with gout. We compared
cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor …

Gout is a picturesque presentation of uric acid disturbance. It is the most well understood
and described type of arthritis. Its epidemiology is studied. New insights into the …

Objectives To review the literature and provide an update on the mechanisms of action and
therapeutic uses of oral colchicine in arthritis and inflammatory conditions. Methods We …

Gout is the most common cause of inflammatory arthritis worldwide. In UK general practice,
the overall prevalence has increased from 1.4% in 1999 to 2.49% in 2012 [1], despite the …

Gout is the most common form of inflammatory arthritis and is a multifactorial disease
typically characterized by hyperuricemia and monosodium urate crystal deposition …

Gout is a disorder that manifests as a spectrum of clinical and pathologic features built on a
foundation of an excess body burden of uric acid, manifested in part by hyperuricemia …

Colchicine is an ancient medication that is currently approved for the treatment of gout and
FMF. However, colchicine has a wide range of anti-inflammatory activities, and studies …